Search results
Results from the WOW.Com Content Network
All PDE5 inhibitors are generally well tolerated. [1] The occurrence of side effects, or adverse drug reactions (ADRs), with PDE5 inhibitors depends on the dose and type of agent. [1] Headache is a very common ADR, occurring in >10% of patients. Other common ADRs include: dizziness, flushing, dyspepsia, nasal congestion or rhinitis. [6]
The major PDE5 inhibitors (a subset of the phosphodiesterase inhibitors) are sildenafil, tadalafil, vardenafil, and avanafil, and although all share the same mechanism of action each has unique pharmacokinetic and pharmacodynamic properties which dictate their suitability in various conditions and their side effect profile. [3]
The most commonly available PDE5 inhibitors are sildenafil (Viagra), [14] vardenafil (Levitra), [15] tadalafil (Cialis), [16] and avanafil (Stendra). [17] PDE5 inhibitors are not routinely prescribed as first line treatment for erectile dysfunction. This is as they cause unwanted side effects like hair loss, headache, and nausea (among others ...
Adibendan; Aminophylline; Aminophylline dihydrate; Amipizone; Apremilast; Arofylline; Atizoram; Befuraline; Bemarinone hydrochloride; Bemoradan; Benafentrine; Bucladesine
Inhibitors of PDE can prolong or enhance the effects of physiological processes mediated by cAMP or cGMP by inhibition of their degradation by PDE. [13] Sildenafil (Viagra) is an inhibitor of cGMP-specific phosphodiesterase type 5, which enhances the vasodilatory effects of cGMP in the corpus cavernosum and is used to treat erectile dysfunction.
2.5 Histone deacetylase inhibitors: Panobinostat: add: add: add: add Romidepsin: IV: Histone deacetylase inhibitor, hence inducing alterations in gene expression in the affected cells. Peripheral and cutaneous T cell lymphoma. Electrolyte anomalies, anaemia, thrombocytopenia, neutropenia, lymphopenia and ECG anomalies. Valproate [Note 1] PO, IV ...
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
Main page; Contents; Current events; Random article; About Wikipedia; Contact us